Pfizer Inc. has chosen to donate the rights of its royalties from the sale of Bavencio (avelumab) in the United States to the American Association for Cancer Research.
Immunotherapy has changed the course of blood cancers and melanomas, but is stubbornly ineffective for the treatment of most epithelial solid cancers—the cancers that kill about 90% of the more than 600,000 Americans who die of cancer each year.
